tbuckley/cabot-search huggingface dataset:
ANGI-11. BONE MARROW-DERIVED MESENCHYMAL STEM CELLS-MEDIATED RADIORESISTANCE IN GLIOBLASTOMA ANGIOGENESIS
Authors: Tansy Zhao, Julie Metcalf, Kenneth Aldape, Gelareh Zadeh
Journal: Neuro-Oncology (2016)

As the central component of heightened vascularization in glioblastoma (GBM), endothelial cells (EC) are arguably the most responsive stromal cells in the tumor microenvironment (TME) during conventional treatment using ionizing radiation (IR) and have important implication in cancer progression as well as therapy-resistance. Although the inherent tumor tropism and angiogenic property of mesenchymal stem cells (MSC) has been documented in GBM, little is known about the function of MSC that are recruited to the GBM Tumor microenvironment. To elucidate the effect of MSC on irradiated EC, we studied the influence of IR, MSC or MSC condition media (CM) on human umbilical vein endothelial cells (HUVECs). IR decreased HUVEC cell proliferation at 24 and 48 hours whilst MSCCM increased cell proliferation at 48 hours. MSCCM doubled the viable number of non-irradiated HUVECs at 48 hours. IR caused phosphorylation of p53 in HUVECs regardless of MSC presence. While 2Gy of radiation was able to transiently increase p-ATM level at 4 hours post IR, MSCCM prolonged this process up to 8 hours. IR preferentially increased p-Akt levels (but not p-ERK1/2) at 8 hours post IR while MSCCM advanced this event to 4 hours and amplified it by two folds when given 15Gy. IR was found to up-regulate mRNA levels of CXCL5, CXCL10, ICAM1, VCAM1 and tissue factor in a dose-dependent manner whereas MSC co-culture boosted the expression of above angiogenic factors. Interestingly, up-regulation of the same set of IR-driven genes in GBM was positively correlated with poor survival in the TCGA GBM database, a strong correlation that was absent if using gene list that was obtained from IR and MSC combine treatment in HUVEC. These findings suggest that MSC promotes angiogenesis in GBM by facilitating the IR-induced active state as well as the effectiveness of DNA damage repair in endothelial cells.
Feasibility of testing core needle biopsies <i>ex vivo</i> in the ChemoFx assay
Authors: J. A. O’Shaughnessy, F. Holmes, P. Beitsch, J. Cunningham, H. Gallion, A. Backner, B. Hellerstedt, J. Pippen, S. Vukelja, B. Dupree
Journal: Journal of Clinical Oncology (2006)

20073 Background: Multiple chemotherapy options exist for the treatment of primary breast cancer. While response rates are good, many patients are treated with unnecessary or ineffective chemotherapy. Inadequate treatments are partly due to the lack of accurate predictors of response in individual patients. To predict an individual’s response to therapy, ex vivo chemosensitivity and resistance assays (CSRAs) have long been evaluated, but have been limited by technical difficulties, including the need for large (1–2 gm) amounts of fresh tissue. However, these problems have largely been overcome with new technology. Novel methods used in Precision Therapeutics’ ChemoFx assay allow for testing smaller amounts of tissue (35 mg). The reduced tissue requirement is crucial in the breast cancer setting, as the diagnosis is often made by percutaneous biopsy. The goals of the study were to determine the growth success rate of culturing epithelial cells from breast tissue core needle biopsies and the feasibility of testing the cells in the assay. Methods: A prospective feasibility study involving women with invasive primary breast cancer. One to four core needle biopsy specimens were collected using a 14 gauge needle (est. per patient yield &lt;50 mg) and submitted to Precision Therapeutics. A primary culture of each specimen was established and the ex vivo chemoresponse profiles of each culture were evaluated. Drugs tested included capecitabine, cisplatin, cyclophosphamide, docetaxel, doxorubicin, epirubicin, etoposide, 5-fluorouracil, gemcitabine, irinotecan, paclitaxel, and vinorelbine. Results: 21 of 25 (84%, 95% CI: 68% to 97%) specimens grew successfully; all 21 were tested for chemoresponsiveness with the assay. Of the 4 subjects with unsuccessful ex vivo cultures, 2 had no growth, 1 failed plating for culture, and 1 failed IHC testing due to overgrowth of non-epithelial cells. The average number of drugs tested for each specimen was 7 (range: 1–15). Conclusions: This study demonstrates that core needle biopsies from primary breast tumors can be successfully cultured and tested for chemoresponsiveness using the ChemoFx assay. The ability to perform ex vivo chemoresponse testing on core needle biopsies greatly increases the utility of the assay in adjuvant or neoadjuvant primary breast cancer settings. [Table: see text]
Family History of Venous Thromboembolism (VTE) and the Risk of VTE Recurrence in Patients with a First Unprovoked VTE: A Multicenter Prospective Cohort Study
Authors: Karine Gauthier, Elham Sabri, Susan R. Kahn, Philip S Wells, David Anderson, Gregoire Le Gal, Susan Solymoss, Mark A. Crowther, Arnaud Perrier, Richard H. White, Michael J. Kovacs, Marc Carrier, Marc A. Rodger
Journal: Blood (2011)
Continued Low-Dose Decitabine (DAC) Is an Active First-Line Treatment of Older AML Patients: First Results of a Multicenter Phase II Study.
Authors: Michael Lübbert, Björn Rüter, Mathias Schmid, Sabine Knipp, Ulrich Germing, Christiane Dobbelstein, Hartmut Eimermacher, Barbara Deschler, Rainer Claus, Richard Schlenk, Arnold Ganser, Hartmut Döhner, Claudia Schmoor, Hartmut Henß
Journal: Blood (2005)
Comparison of Immune Reconstitution after Unmanipulated HLA-Mismatched/Haploidentical Blood and Marrow Transplantation and Unmanipulated HLA-Matched Sibling Transplantation in Patients with Hematological Malignancies.
Authors: Ying jun Chang, Xiang yu Zhao, Ming rui Huo, Xiao hua Luo, Lan ping Xu, Dai hong Liu, Kai yan Liu, Xiao Jun Huang
Journal: Blood (2008)
TRENDS IN LIVER TRANSPLANTATION FOR PRIMARY BILIARY CIRRHOSIS IN THE NETHERLANDS 1988-2008
Authors: Edith M. Kuiper, Bettina E. Hansen, Herold J. Metselaar, Robert A. De Man, Elizabeth B. Haagsma, Bart Van Hoek, Henk R. van Buuren
Journal: Hepatology (2009)

A decrease in the need for liver transplantations (LTX) in Primary Biliary Cirrhosis (PBC), possibly related to treatment with ursodeoxycholic acid (UDCA), has been reported in the USA and UK. The aim of this study was to assess LTX requirements in PBC over the past 20 years in the Netherlands. Analysis of PBC transplant data of the Dutch Organ Transplant Registry during the period 1988-2008, including both absolute and proportional numbers. The indication for LTX was categorized as liver failure, hepatocellular carcinoma or poor quality of life (severe fatigue or pruritus). Data were analysed for two decades: 1.1.1988-31.12.1997 (1st) and 1.1.1998-31.12.2007 (2nd). The severity of disease was quantified using MELD scores. To fit lines which show trends over time we applied a linear regression model. A total of 110 patients (87% women) was placed on the waiting list. 105 patients were transplanted (1st: 61, 2nd: 44), 5 (5%) died while listed. The absolute annual number of LTX for PBC slightly decreased during the 20 year period, the proportional number decreased significantly. At the time of LTX the mean age was 53.6 yrs. (1st: 53.4, 2nd: 53.8), the mean MELD score 13.9 (1st:14.5, 2nd:13.0). The median interval from diagnosis to LTX was 90.5 months (1st:86.5, 2nd: 93.5). 69% of patients was treated with UDCA (1st 38%, 2nd 82%). Over the past 20 years the absolute number of LTX for PBC in the Netherlands showed a tendency to decrease whereas the proportional decrease was significant. There was a trend over time toward earlier transplantation.
Microarray Analysis of PU.1-Induced Growth Arrest and Apoptosis of Myeloma Cell Lines.
Authors: Shikiko Ueno, Hiro Tatetsu, Naoko Harada, Hiroyuki Hata, Tadafumi Iino, Hiroaki Niiro, Koichi Akashi, Daniel G. Tenen, Hiroaki Mitsuya, Yutaka Okuno
Journal: Blood (2007)
Mutational Spectrum In Chronic Myelomonocytic Leukemia Includes Genes Associated with Epigenetic Regulation Such as UTX and EZH2
Authors: Anna Jankowska, Hideki Makishima, Ramon V. Tiu, Hadrian Szpurka, Yun Huang, Yuka Sugimoto, Courtney Prince, Christine L. O'Keefe, Eric Hsi, Alan F. List, Mikkael A. Sekeres, Anjana Rao, Michael A McDevitt, Jaroslaw P Maciejewski
Journal: Blood (2010)
GTx011, a Potent Allosteric Modifier of Hemoglobin Oxygen Affinity, Prevents RBC Sickling in Whole Blood and Prolongs RBC Half-Life in Vivo in a Murine Model of Sickle Cell Disease
Authors: Kobina Dufu, Donna Oksenberg, Chengjing Zhou, Athiwat Hutchaleelaha, David R. Archer
Journal: Blood (2014)
Manipulating PML SUMOylation via Silencing UBC9 and RNF4 Regulates Cardiac Fibrosis
Authors: Yu Liu, Dan Zhao, Fang Qiu, Ling-Ling Zhang, Shang-Kun Liu, Yuan-Yuan Li, Mei-Tong Liu, Di Wu, Jia-Xin Wang, Xiao-Qing Ding, Yan-Xin Liu, Chang-Jiang Dong, Xiao-Qi Shao, Bao-Feng Yang, Wen-Feng Chu
Journal: Molecular Therapy (2017)

The promyelocytic leukemia protein (PML) is essential in the assembly of dynamic subnuclear structures called PML nuclear bodies (PML-NBs), which are involved in regulating diverse cellular functions. However, the possibility of PML being involved in cardiac disease has not been examined. In mice undergoing transverse aortic constriction (TAC) and arsenic trioxide (ATO) injection, transforming growth factor β1 (TGF-β1) was upregulated along with dynamic alteration of PML SUMOylation. In cultured neonatal mouse cardiac fibroblasts (NMCFs), ATO, angiotensin II (Ang II), and fetal bovine serum (FBS) significantly triggered PML SUMOylation and the assembly of PML-NBs. Inhibition of SUMOylated PML by silencing UBC9, the unique SUMO E2-conjugating enzyme, reduced the development of cardiac fibrosis and partially improved cardiac function in TAC mice. In contrast, enhancing SUMOylated PML accumulation, by silencing RNF4, a poly-SUMO-specific E3 ubiquitin ligase, accelerated the induction of cardiac fibrosis and promoted cardiac function injury. PML colocalized with Pin1 (a positive regulator for TGF-β1 mRNA expression in PML-NBs) and increased TGF-β1 activity. These findings suggest that the UBC9/PML/RNF4 axis plays a critical role as an important SUMO pathway in cardiac fibrosis. Modulating the protein levels of the pathway provides an attractive therapeutic target for the treatment of cardiac fibrosis and heart failure.
Junctional Adhesion Molecule-A (JAM-A/JAM-1/F11R) Marks Long-Term Repopulating Hematopoietic Stem Cells.
Authors: Yasuyoshi Sugano, Masaki Takeuchi, Ayami Hirata, Hirokazu Matsushita, Toshio Kitamura, Minoru Tanaka, Atsushi Miyajima
Journal: Blood (2007)
Fibroblast drug scavenging increases intratumoural gemcitabine accumulation in murine pancreas cancer
Authors: E Hessmann, M S Patzak, L Klein, N Chen, V Kari, I Ramu, T E Bapiro, K K Frese, A Gopinathan, F M Richards, D I Jodrell, C Verbeke, X Li, R Heuchel, J M Löhr, S A Johnsen, T M Gress, V Ellenrieder, A Neesse
Journal: Gut (2017)

Objective Desmoplasia and hypovascularity are thought to impede drug delivery in pancreatic ductal adenocarcinoma (PDAC). However, stromal depletion approaches have failed to show clinical responses in patients. Here, we aimed to revisit the role of the tumour microenvironment as a physical barrier for gemcitabine delivery. Design Gemcitabine metabolites were analysed in LSL-Kras G12D/+ ; LSL-Trp53 R172H/+ ; Pdx-1-Cre (KPC) murine tumours and matched liver metastases, primary tumour cell lines, cancer-associated fibroblasts (CAFs) and pancreatic stellate cells (PSCs) by liquid chromatography-mass spectrometry/mass spectrometry. Functional and preclinical experiments, as well as expression analysis of stromal markers and gemcitabine metabolism pathways were performed in murine and human specimen to investigate the preclinical implications and the mechanism of gemcitabine accumulation. Results Gemcitabine accumulation was significantly enhanced in fibroblast-rich tumours compared with liver metastases and normal liver. In vitro, significantly increased concentrations of activated 2′,2′-difluorodeoxycytidine-5′-triphosphate (dFdCTP) and greatly reduced amounts of the inactive gemcitabine metabolite 2′,2′-difluorodeoxyuridine were detected in PSCs and CAFs. Mechanistically, key metabolic enzymes involved in gemcitabine inactivation such as hydrolytic cytosolic 5′-nucleotidases (Nt5c1A, Nt5c3) were expressed at low levels in CAFs in vitro and in vivo, and recombinant expression of Nt5c1A resulted in decreased intracellular dFdCTP concentrations in vitro. Moreover, gemcitabine treatment in KPC mice reduced the number of liver metastases by &gt;50%. Conclusions Our findings suggest that fibroblast drug scavenging may contribute to the clinical failure of gemcitabine in desmoplastic PDAC. Metabolic targeting of CAFs may thus be a promising strategy to enhance the antiproliferative effects of gemcitabine.
Abstract B31: Development of an implanted pump for metronomic delivery of chemotherapy and biological compounds: the virtue of local delivery
Authors: Thomas C. Chen, Frank Adell, Joshua Schachar
Journal: Cancer Research (2017)

Abstract The development of an implanted pump that can locally and metronomically deliver drugs and biological agents is crucial in the treatment of cancer. For the last eight years, we have worked on an implanted pump that can deliver precisely at microliter doses. The Ipsum pump (Cognos Therapeutics) has three components: a double lumen catheter, a sampling reservoir, and a pump. The drug is pumped out of the bellows (5 ml) via a hermetically sealed MRI compatible piezoelectric pump. The drug is delivered via the delivery catheter lumen into the target. The sampling lumen can draw from the target to determine levels of drug delivered, allowing for in-vivo pharmacokinetic measurements. The reservoir is connected to the catheter and can be used to sample fluid. An optical sensor (embedded spectrophotometer) is set a specific frequency to determine absorbance for pharmacokinetic measurements of drug delivered. The pump is powered by a long term battery (good for up to five years) and is wirelessly controlled externally by the physician operator. Our first disease model will be delivery of methotrexate to the cerebrospinal fluid in the treatment of leptomeningeal carcinomatosis. Citation Format: Thomas C. Chen, Frank Adell, Joshua Schachar. Development of an implanted pump for metronomic delivery of chemotherapy and biological compounds: the virtue of local delivery. [abstract]. In: Proceedings of the AACR Special Conference on Engineering and Physical Sciences in Oncology; 2016 Jun 25-28; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2017;77(2 Suppl):Abstract nr B31.
The microRNA-449 family inhibits TGF-β-mediated liver cancer cell migration by targeting SOX4
Authors: Maria Sandbothe, Reena Buurman, Nicole Reich, Luisa Greiwe, Beate Vajen, Engin Gürlevik, Vera Schäffer, Marlies Eilers, Florian Kühnel, Alejandro Vaquero, Thomas Longerich, Stephanie Roessler, Peter Schirmacher, Michael P. Manns, Thomas Illig, Brigitte Schlegelberger, Britta Skawran
Journal: Journal of Hepatology (2017)
Cancer/Testis Antigens MAGE-C1/CT7 and MAGE-C2/CT10 Are Expressed in 90% of Multiple Myeloma Samples and Can Be Explored in Combined Immunotherapy for This Malignancy
Authors: Fabricio de Carvalho, Veruska Lia, Fook Alves, Walter Moisés, Tobias Braga, Celso Vieira Xavier, Gisele Wally Braga Colleoni
Journal: Blood (2012)
A Functional Thrombopoietin Receptor Is Required for Full Expression of Phenotype in a JAK2 V617F Transgenic Mouse Model of Polycythemia Vera
Authors: Jerry L. Spivak, Akil Merchant, Donna M. Williams, Ophelia Rogers, Wanming Zhao, Alison R. Moliterno, Zhizhuang Joe Zhao
Journal: Blood (2012)
A Heterogeneous Response Pattern to Interferon-alpha2 with Induction of a Significant Decrease in the Calreticulin Mutant Allele Burden in a Subset of Patients with Essential Thrombocythemia and Primary Myelofibrosis
Authors: Sabrina Cordua, Lasse Kjaer, Morten Orebo Holmström, Niels Pallisgaard, Vibe Skov, Hans Hasselbalch
Journal: Blood (2015)
Gene Expression Profiling Reveals 5-Azacytidine to Be a Novel, Potentially Effective Therapy for Poor-Prognosis Patients with Multiple Myeloma.
Authors: Sascha Tuchman, Chaitanya Acharya, William Mostertz, William Barry, Cristina Gasparetto, Bart Barlogie, Anil Potti, John D Shaughnessy
Journal: Blood (2009)
Compassionate Use of Intrathecal Depot Cytarabine (DepoCyte®) in Central Nervous System (CNS) Involvement in Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma in Spain: Report of 10 Cases.
Authors: Juan-Manuel Sancho, Pilar Giraldo, Maria-Jose Romero, Victoria Martin-Reina, Eugenio Gimenez, Elena Ruiz, Plaza Josefa, Carmen Monteserin, Eva Sanchez-Garcia, Rodrigo Martino, Jose Sarra, Luis Palomera, Josep-Maria Ribera
Journal: Blood (2006)
Type 2 Diabetes and Comorbid Symptoms of Depression and Anxiety: Longitudinal Associations With Mortality Risk
Authors: Kiyuri Naicker, Jeffrey A. Johnson, Jens C. Skogen, Douglas Manuel, Simon Øverland, Børge Sivertsen, Ian Colman
Journal: Diabetes Care (2017)

Depression is strongly linked to increased mortality in individuals with type 2 diabetes. Despite high rates of co-occurring anxiety and depression, the risk of death associated with comorbid anxiety in individuals with type 2 diabetes is poorly understood. This study documented the excess mortality risk associated with symptoms of depression and/or anxiety comorbid with type 2 diabetes.Using data for 64,177 Norwegian adults from the second wave of the Nord-Trøndelag Health Study (HUNT2), with linkage to the Norwegian Causes of Death Registry, we assessed all-cause mortality from survey participation in 1995 through to 2013. We used Cox proportional hazards models to examine mortality risk over 18 years associated with type 2 diabetes status and the presence of comorbid affective symptoms at baseline.Three clear patterns emerged from our findings. First, mortality risk in individuals with diabetes increased in the presence of depression or anxiety, or both. Second, mortality risk was lowest for symptoms of anxiety, higher for comorbid depression-anxiety, and highest for depression. Lastly, excess mortality risk associated with depression and anxiety was observed in men with diabetes but not in women. The highest risk of death was observed in men with diabetes and symptoms of depression only (hazard ratio 3.47, 95% CI 1.96, 6.14).This study provides evidence that symptoms of anxiety affect mortality risk in individuals with type 2 diabetes independently of symptoms of depression, in addition to attenuating the relationship between depressive symptoms and mortality in these individuals.
Numerous Genomic Abnormalities in AML with Normal Karyotype.
Authors: Tadayuki Akagi, Seishi Ogawa, Go Yamamoto, Yasuhito Nannya, Masashi Sanada, Norihiko Kawamata, Carl W. Miller, Martin Dugas, Susanne Schnittger, Torsten Haferlach, Claudia Haferlach, H. Phillip Koeffler
Journal: Blood (2007)
DNA Methylation and Gene Expression Analysis in a Phase II Randomized Study of Decitabine Vs. Decitabine Plus Valproic Acid in MDS and AML.
Authors: Ryan J Castoro, Noel J Raynal, Xuelin Huang, Carlos E. Bueso-Ramos, Guillermo Garcia-Manero, Hagop M. Kantarjian, Jean-Pierre J Issa
Journal: Blood (2009)
Clinical Implications of Anemia in Heart Failure (HF) Patients (pts).
Authors: Dolores Puente, Cecilia Colorio, Roxana Ratto, Martin Descalzo, Andrea Rossi, Francisco Perea, Mirta Diez, Ricardo Forastiero, Maria Tabares, Liliana Favaloro, Gonzalo Pombo, Leonardo Feldman
Journal: Blood (2007)
Rituximab-Mediated Sensitization of B-NHL Cells Lines to TRAIL-Induced Apoptosis: Involvement of YY1 Suppression and DR5 Upregulation.
Authors: Mario I. Vega, Sara Huerta-Yepez, Stavroula Baritaki, Cesar Bonilla-Gonzalez, Benjamin Bonavida
Journal: Blood (2006)
Clinical impact of sarcopenia on prognosis in pancreatic ductal adenocarcinoma: A retrospective cohort study
Authors: Go Ninomiya, Tsutomu Fujii, Suguru Yamada, Norimitsu Yabusaki, Kojiro Suzuki, Naoki Iwata, Mitsuro Kanda, Masamichi Hayashi, Chie Tanaka, Goro Nakayama, Hiroyuki Sugimoto, Masahiko Koike, Michitaka Fujiwara, Yasuhiro Kodera
Journal: International Journal of Surgery (2017)
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Recipients with Hematological Malignancies
Authors: Yi-Bin Chen, Jennifer Le-Rademacher, Deidre Marie Kiefer, Mehdi Hamadani, John F. DiPersio, Mark R Litzow, Michael Craig, Mitchell E. Horwitz, Andrew Artz, Brian McClune, Edmund K Waller, Hugo F. Fernandez, Hien Kim Duong, Hati Kobusingye, Mandi Proue, Rebecca J. Drexler, Mary M. Horowitz, John P. Miller, Steven M. Devine
Journal: Blood (2015)
Front-Line High-Dose Chemotherapy (HDT) Combined with Rituximab for Adults with Aggressive Large B-Cell Lymphoma (DLBCL) : Goelams 074 Trial.
Authors: Noel-Jean Milpied, Thierry Lamy, Philippe Casassus, Eric Deconninck, Remy Gressin, Herve Maisonneuve, Christine Le Maignan, Jean-Francois Ramee, Olivier Tournilhac, Jacqueline Dugay, Eric Legouffe, Vincent Delwail, Philippe Colombat
Journal: Blood (2004)
“Unresponsive” complaints system is failing NHS patients
Authors: Gareth Iacobucci
Journal: BMJ (2017)

The NHS’s national complaints watchdog has failed to improve the way it handles grievances from patients and their families, a new report from the Patients Association has found.

The association published a damning report in 2015 cataloguing the negative experiences and dealings that patients and their families had reported with the Parliamentary and Health Service Ombudsman. In a follow-up report the association said that it had continued to receive a high number of calls from patients who felt that the watchdog was providing a poor quality service.1

The association analysed nearly …
Patient Factors Associated with Enrollment on an Acute Myeloid Leukemia Phase III Clinical Trial: A Report from the Children’s Oncology Group
Authors: Pooja Rao, Yimei Li, Todd A. Alonzo, Lillian Sung, Robert B. Gerbing, Kelly D Getz, Alix E. Seif, Tamara P. Miller, Yuan-Shung Huang, Rochelle Bagatell, Matthew Hall, Brian T. Fisher, Alan S. Gamis, Richard Aplenc
Journal: Blood (2014)
A Phase 1/2 Study of NS-018, an Oral JAK2 Inhibitor, in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (pPV MF), or Post-Essential Thrombocythemia Myelofibrosis (pET MF)
Authors: Srdan Verstovsek, Moshe Talpaz, Ellen Ritchie, Martha Wadleigh, Olatoyosi Odenike, Catriona Jamieson, Brady Stein, Tomonori Uno, Ruben A. Mesa
Journal: Blood (2015)
Common VWF Haplotypes in Normal African-Americans and Caucasians Recruited into the ZPMCB-VWD and Their Impact on VWF Laboratory Testing.
Authors: Veronica H. Flood, B.C. Kautza, C.A. Miller, B.R. Branchford, J.C. Gill, S.L. Haberichter, P.A. Morateck, P.A. Christopherson, C.L. Perry, K.D. Friedman, D.B. Bellissimo, T.C. Abshire, J.A Di Paola, W.K. Hoots, C. Leissinger, J.M. Lusher, M.V. Ragni, Ad Shapiro, D. Lillicrap, A.C. Goodeve, I.R. Peake, R.R. Montgomery
Journal: Blood (2007)
Absence of Somatically Acquired JAK1 Mutations in Adult T-Cell Leukemia/Lymphoma.
Authors: Takuro Kameda, Kotaro Shide, Haruko Shimoda, Tomonori Hidaka, Keiko Katayose, Yasuhiro Taniguchi, Kohich Maeda, Yoko Kubuki, Takuya Matsunaga, Kazuya Shimoda
Journal: Blood (2009)
High Response Rate and Low Toxicity of Rituximab, Vinorelbine, Ifosfamide, Mitoxantrone and Prednisone Combination for the Treatment of Diffuse Large B Cell Lymphoma In First Relapse: Early Results of the R-NIMP GOELAMS Study.
Authors: Emmanuel Gyan, Delphine Senecal, Philippe Quittet, Charles Foussard, Anne Banos, Steven Le Gouill, Charles Dauriac, Julie Léger, Jean Fontan, Diane Damotte, Hervé Maisonneuve, Magda Alexis, Francois Dreyfus, Stéphane Courby, Jean-Louis Dutel, Olivier Tournilhac, Kamel Laribi, Philippe Solal-Céligny, Annick Le Pourhiet-Le Mevel, Nina Arakelyan, Henry Jardel, Remy Gressin
Journal: Blood (2010)